Positive Thrombo inCode clinical results

GENinCode Plc are pleased to announce the publication of its Thrombo inCode® prospective case-control study performed at the Karolinska Institute, Sweden. The positive clinical results strengthen [...]

Admission to trading RNS

GENinCode the predictive genetics and cardiovascular disease company focused on the prevention of cardiovascular disease is thrilled to announce the completion of its IPO and subsequent listing [...]

GENinCode Appoints New Chairman

GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes [...]


The 34th National Congress of the Italian Society for the Study of Atherosclerosis (SISA) took place virtually on the 22nd of November. The Congress addressed several topics of interest in the [...]

Genome UK_the future of healthcare

The much-anticipated UK Genomic Health Strategy has now been published! ‘The strategy sets out an ambitious and compelling vision for how to create the most advanced genomic healthcare [...]


As part of our ongoing plan to combat the SARS-CoV-2 virus (Covid-19) and in response to the needs of our customers and collaborating health care partners, GEN inCode are now offering Covid-19 [...]

GEN inCode

On September 12, 2018 GEN inCode acquired the personalized medicine service of the products Cardio inCode®, Lipid inCode®, SudD inCode® and Thrombo inCode® and the assets and know-how of the [...]